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A B S T R A C T
Purpose: This multicenter, prospective study investigates the efﬁcacy and safety of lacosamide
adjunctive therapy in pediatric and adult patients with uncontrolled epilepsy.
Method: This study was carried out between September 2010 and December 2011 at 16 Italian and 1
German neurologic centers. Lacosamide was added to the baseline therapy at a starting dose of 1 mg/kg/
day in patients aged <16 years (group A) and 100 mg daily in subjects aged 16 and older (group B), and
titrated to the target dose, ranging from 3 to 12 mg/kg/day or from 100 to 600 mg daily, respectively.
After completing the titration period, patients entered a 12-month maintenance period and they were
followed up at 3, 6 and 12 months. The primary assessment of efﬁcacy was based on the change from
baseline in seizure frequency per 28 days and was evaluated at 3, 6 and 12 months as follows: number
and proportion of 100% responders, 50% responders, non-responders and worsening patients. Safety
evaluation was also performed at 3, 6 and 12 months.
Results: A total of 118 patients (59 group A, 59 group B) with uncontrolled generalized and focal epilepsy
were enrolled. Patient mean  SD age was 15.9  6.80 years and the age range was 4–38 years. At 3-month
evaluation, of 118 treated patients 56 subjects (47.4% group A; 47.4% group B; p = 0.8537) experienced at
least a 50% reduction in seizure frequency. At 6 and 12-month follow-up, the 50% responders were 57 (52.5%
group A; 44.1% group B; p = 0.4612) and 51 (47.4% group A; 39% group B; p = 0.4573), respectively. Thirty-ﬁve
subjects (30.5% group A; 28.8% group B; p = 1) experienced side effects during the treatment period. The most
common adverse events were dyspepsia for group A and dizziness for group B.
Conclusion: Lacosamide may be a useful and safe pharmacological treatment option for both pediatric
and adult patients with uncontrolled seizures.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at SciVerse ScienceDirect
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Lacosamide was approved in August 2008 by the European
Commission and in October 2008 by the Food and Drug
Administration as an adjunctive therapy for partial onset seizures
in patients with epilepsy aged 16 and older (Europe)/17 and older
(United States).
Lacosamide ([R]-2-acetamido-N-benzyl-3-methoxypropiona-
mide) is a unique functionalized amino acid speciﬁcally synthe-
sized for use as an antiepileptic drug (AED).1,2 It is available in
dose-equivalent oral and intravenous formulations.3
Initial investigations suggested that LCM might have two
mechanisms of action: increase of the slow inactivation of the
voltage-gated sodium channels and interference with collapsing-
response mediator protein 2 (CRMP-2).1,4–6 However, the CRMP-2
component has recently been refuted based on new experimental
evidence.7Three large phase IIb/III randomized, placebo-controlled
trials were carried out to evaluate the clinical utility of oral
lacosamide as adjunctive therapy for refractory partial-onset
seizures in adults aged 16–70 years.8–10 Initially, a phase IIb
multinational trial (SP667) evaluated lacosamide 200, 400, and
600 mg/day compared with placebo as adjunctive treatment in 418
adults with uncontrolled partial onset seizures taking 1–2
concomitant AEDs.8 Reductions in seizure frequency and the
proportion of patients with at least a 50% reduction in seizure
frequency (50% responder rate) with lacosamide 400 and 600 mg/
day were statistically signiﬁcant compared with placebo in the
primary intent-to-treat (ITT) population.8 Two additional phase III
trials (SP755 and SP754) were conducted in parallel to conﬁrm
these results in an expanded population of patients, taking up to
three AEDs with or without additional vagus nerve stimulation.9,10
The potential usefulness of lacosamide in pediatric patients with
uncontrolled seizures has been investigated in four small recent
studies.11–14
To the best of our knowledge, there is no study comparing the
usefulness of lacosamide treatment in adults and children. The
purpose of the present multicentric study was to evaluate the
safety and efﬁcacy of lacosamide adjunctive therapy in both
pediatric and adult populations.
2. Materials and methods
The present report is a multicenter, prospective, open-label
treatment study carried out between September 2010 and
December 2011 at 16 Italian and 1 German centers.
The study protocol, amendments and informed consent were
reviewed by ethics committees for each site. All patients or their
legal representatives gave written informed consent before study
participation.
Males and females, aged between 4 and 40 years, with
uncontrolled generalized and focal epilepsy were eligible. Diagno-
sis was based on the classiﬁcation of epileptic seizures (Commis-
sion on Classiﬁcation and Terminology of the International League
Against Epilepsy, 2005–2009).15
Inclusion criteria required patients to have had at least a 1-year
history of epileptic seizures despite treatment with at least two
AEDs (concurrently or sequentially). During the 12-week period
before enrollment, patients were to have had at least 2 seizures per
28 days on average. In addition, patients were to have been taking a
stable dosage regimen of 1–4 AEDs, with or without vagus nerve
stimulation (VNS), in the 4 weeks before enrollment.
The following exclusion criteria were applied: age less than four
years, metabolic and systemic disorders, poor compliance, refused
informed consent. Females who were pregnant, breast-feeding, or
of childbearing potential and not using approved contraception
methods were also excluded.After enrollment, plasma samples were drawn to investigate
complete blood count (CBC), transaminasemia, azotemia, glyce-
mia, gamma gt levels, PT and PTT tests, ﬁbrinogen levels, serum
cholesterol levels, triglyceride levels, electrolytes balance, serum
thyroid hormones; urinalysis, sleep/awake EEG, ECG and brain
RMN were also performed.
Seizure frequency during the 4 weeks preceding lacosamide
initiation was used as baseline. All patients were divided into two
groups: group A (age < 16 years) taking lacosamide off-label and
group B (age  16 years). Lacosamide was added to a stable dosage
of baseline AEDs and administered orally in the form of syrup or
tablets. Lacosamide was initiated at 1 mg/kg/day in the group A
and 100 mg/day in the group B and titrated in 1 mg/kg/day or
50 mg/day increments per week until the target dose, ranging from
3 to 12 mg/kg/day or from 100 to 600 mg/day respectively, was
met. During the titration period, all patients were reviewed every 2
weeks.
After the titration period, patients entered a 12-month
maintenance period and were followed up at 3, 6 and 12 months.
No change in the dose of lacosamide was permitted during the
maintenance period.
Patients who were unable to tolerate protocol medication and
those experiencing an increase in seizure frequency or status
epilepticus were to discontinue treatment.
The primary assessment of efﬁcacy was based on the change
from baseline in seizure frequency per 28 days and was evaluated
at 3, 6 and 12-month follow-up, as follows: number and proportion
of patients achieving seizure freedom (100% responders); number
and proportion of patients experiencing a 50% or greater reduction
in seizure frequency (50% responders); number and proportion of
patients experiencing less than 50% reduction in seizure frequency
(non-responders); number and proportion of patients having an
increase in seizure frequency (worsening patients). Afterwards
patients were divided into exclusive categories of seizure type
(generalized seizures; focal seizures; focal evolving to bilateral
convulsive seizures; mixed seizures which included patients
experiencing either generalized and focal seizures) and the efﬁcacy
outcomes were analyzed according to this classiﬁcation. Patients
or their caregiver kept daily diaries, which documented seizure
types and seizure frequency from the beginning of baseline until
the last evaluation.
The assessment of safety was performed at 3, 6 and 12 months
and consisted in collecting data on adverse events reported by the
patient or their caregiver or observed by the investigator; patient
withdrawals due to adverse events; changes in laboratory values
(CBC, liver and kidney function tests, urinalysis, plasma concen-
trations of concomitant AEDs), ECG and EEG, vital sign and body
weight measurements, physical and neurologic examination
ﬁndings.
Efﬁcacy and safety outcomes between group A and group B
were compared using the chi-squared test.
Statistical signiﬁcance was based on a probability level (a)
equal to 0.05. All analyses were performed using the statistical
programming language R.
3. Results
3.1. Demographics
A total of 118 patients (59 group A, 59 group B) with
uncontrolled generalized and focal epilepsy were enrolled. Of
118 patients entering the study, all subjects completed the
titration phase and 81 patients completed the maintenance phase.
Of 37 (31.4%) patients discontinuing prematurely (22% group A;
40.7% group B; p = 0.0472), 18 (15.2%) withdrew from the study
due to lack of efﬁcacy (6.8% group A; 23.7% group B; p = 0.0212), 12
Table 1
Patient demographics and characteristics.
Characteristic Group A (n = 59) Group B (n = 59) Total (n = 118)
Age, year
Mean  SD 10.8  3.14 21.0  5.62 15.9  6.80
Range 4–15 16–38 4–38
Sex, n (%)
Male 30 (50.8%) 34 (57.6%) 64 (54.2%)
Female 29 (49.2%) 25 (42.4%) 54 (45.8%)
Weight, kg (mean  SD) 38.0  14.95 63.7  13.10 50.7  19.05
Age of epilepsy onset, year (mean  SD) 2.4  2.16 4.5  4.80 3.5  3.93
Seizure classiﬁcation, n (%)
Generalized seizures 12 (20.3%) 4 (6.8%) 16 (13.6%)
Focal seizures 19 (32.2%) 10 (16.9%) 29 (24.6%)
Focal evolving to bilateral seizures 7 (11.9%) 8 (13.6%) 15 (12.7%)
Mixed seizures 21 (35.6%) 37 (62.7%) 58 (49.1%)
Etiology classiﬁcation, n (%)
Structural/metabolic 40 (67.8%) 38 (64.4%) 78 (66.1%)
Unknown 19 (32.2%) 21 (35.6%) 40 (33.9%)
Concomitant AEDs, n (%)
1 AED 7 (11.9%) 4 (6.8%) 11 (9.3%)
2 AEDs 31 (52.5%) 38 (64.4%) 69 (58.5%)
3 AEDs 17 (28.8%) 14 (23.7%) 31 (26.3%)
4 AEDs 4 (6.8%) 3 (5.1%) 7 (5.9%)
VNS use, n (%) 2 (3.4%) 7 (11.9%) 9 (7.6%)
Baseline seizure frequency per 28 days
Mean  SD 100.2  116.37 53.1  100.37 75.2  110.21
Range 2–600 2–675 2–675
SD, standard deviation; AEDs, antiepileptic drugs; VNS, vagus nerve stimulation.
Fig. 1. Percentage of 50% responders in the groups A and B at 3, 6 and 12-month
evaluations.
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8.5% group B; p = 0.7607) and 7 (5.9%) because of adverse events
(3.4% group A; 8.5% group B; p = 0.4357).
Baseline patient demographics and characteristics are summa-
rized in Table 1. Patient mean  SD age was 15.9  6.80 years and
the age range was 4–38 years; the mean weight was 50.7  19.05 kg
and the mean age of epilepsy onset was 3.5  3.93 years. Among
study population, 16 subjects (12 group A; 4 group B) suffered from
generalized seizures, 29 (19 group A; 10 group B) from focal seizures
(7 from simple partial seizures, 22 from complex partial seizures), 15
(7 group A; 8 group B) from focal seizures evolving to bilateral
convulsive seizures and 58 (21 group A; 37 group B) from mixed
seizures. An underlying structural/metabolic etiology was deter-
mined in 78 cases (40 group A; 38 group B): neural migration disorder
(19), leukoencephalopathy (11), encephalitis (9), encephalopathy (9),
hydrocephalus (8), cortical cerebral atrophy (6), multiple gliosis (5),
poroencephalic lesion (3), hippocampal lesion (2), trisomy 13 (2), ring
chromosome 20 (1), right temporal lobectomy (1), bilateral thalamic
necrosis (1), hypothalamic hamartoma (1). The remaining 40 cases
(19 group A; 21 group B) had no identiﬁable etiology. More precisely,
a structural/metabolic etiology was identiﬁed in 8 (50%) of the 16
subjects with generalized seizures, 16 (55.2%) of the 29 patients with
focal seizures, 12 (80%) of the 15 subjects with focal seizures evolving
to bilateral convulsive seizures and 42 (72.4%) of the 58 patients with
mixed seizures.
Approximately 9.3% of patients were taking 1 concomitant AED,
58.5% 2 concomitant AEDs, 26.3% 3 concomitant AEDs and 5.9%
were taking 4 concomitant AEDs when lacosamide was added to
their treatment regimen. In addition to 1–4 concomitant AEDs, a
total of 7.6% of patients were also using VNS. The 6 concomitant
AEDs most commonly taken by patients in both treatment groups
were: valproate (33.9% group A, 30.5% group B), levetiracetam
(30.5% group A, 18.6% group B), carbamazepine (25.4% group A,
35.6% group B), clobazam (23.7% group A, 15.2% group B),
topiramate (22% group A, 15.2% group B) and lamotrigine (20.3%
group A, 15.2% group B). Despite treatment with 1–4 concomitant
AEDs, at baseline the mean seizure frequency per 28 days was
75.2  110.21. The mean ﬁnal dose of lacosamide was 7.2  2.45 mg/
kg/day in the group A and 327.3  98.5 mg/day in the group B. Thetitration period ranged from 3 to 12 weeks in both treatment groups.
The dosage regimen of concomitant AEDs was not modiﬁed during
lacosamide treatment period. The mean follow-up duration was
11.21  3.59 months, ranging from 3.23 to 14.80 months.
3.2. Efﬁcacy
3.2.1. General efﬁcacy
At 3-month evaluation, of 118 patients entering the mainte-
nance period 56 (47.4%) subjects (47.4% group A; 47.4% group B;
p = 0.8537) experienced at least a 50% reduction in seizure
frequency (Fig. 1), 46 (39%) showed less than 50% reduction in
seizure frequency (33.9% group A; 44.1% group B; p = 0.3453) and
6 (5.1%) were seizure free (6.8% group A; 3.4% group B; p = 0.6752);
of these 6 patients 5 were taking 2 concomitant AEDs (carbamaz-
epine plus topiramate, carbamazepine plus lamotrigine, carba-
mazepine plus levetiracetam, diphenylhydantoin plus
clonazepam and phenobarbital plus topiramate) and 1 was taking
1 concomitant AED (valproic acid) in addition to lacosamide
therapy. Lacosamide appeared to increase seizure frequency in 10
(8.5%) subjects (11.9%) group A; 5.1% group B; p = 0.3214) that
were to discontinue treatment. Known seizure types for these
Table 2
Efﬁcacy by seizure type.
Seizure type 3-Month follow-up 6-Month follow-up 12-Month follow-up
100%
responders
n (%)
50%
responders
n (%)
Non-
responders
n (%)
Worsening
patients
n (%)
100%
responders
n (%)
50%
responders
n (%)
Non-
responders
n (%)
Worsening
patients
n (%)
100%
responders
n (%)
50%
responders
n (%)
Non-
responders
n (%)
Worsening
patients
n (%)
Generalized
Group A (n=12) 1 (8.3%) 4 (33.3%) 3 (25%) 4 (33.3%) – 4 (33.3%) 2 (16.7%) – – 4 (33.3%) 1 (8.3%) –
Group B (n=4) 1 (25%) – 2 (50%) 1 (25%) 1 (25%) – 2 (50%) – 1 (25%) – 1 (25%) –
Total (n=16) 2 (12.5%)c 4 (25%) 5 (31.2%) 5 (31.2%)a,b 1 (6.3%) 4 (25%)a 4 (25%) – 1 (6.3%) 4 (25%)a 2 (12.5%) –
Focal
Group A (n=19) 3 (15.8%) 7 (36.8%) 8 (42.1%) 1 (5.3%) – 12 (63.2%) 6 (31.6%) – – 11 (57.9%) 4 (21.1%) –
Group B (n=10) 1 (10%) 6 (60%) 3 (30%) – – 7 (70%) 3 (30%) – – 7 (70%) 1 (10%) –
Total (n=29) 4 (13.8%)d 13 (44.8%) 11 (37.9%) 1 (3.5%)a – 19 (65.5%)a 9 (31%) – – 18 (62.1%)a 5 (17.2%) –
Focal evolving to bilateral seizure
Group A (n=7) – 5 (71.4%) 2 (28.6%) – – 3 (42.9%) 4 (57.1%) – – 2 (28.6%) 5 (71.4%) –
Group B (n=8) – 4 (50%) 4 (50%) – – 3 (37.5%) 4 (50%) – – 2 (25%) 2 (25%) –
Total (n=15) – 9 (60%) 6 (40%) – – 6 (40%) 8 (53.3%) – – 4 (26.7%) 7 (46.7%)b –
Mixed
Group A (n=21) – 12 (57.1%) 7 (33.3%) 2 (9.5%) – 12 (57.1%) 7 (33.3%) – – 11 (52.4%) 8 (38.1%) –
Group B (n=37) – 18 (48.7%) 17 (45.9%) 2 (5.4%) – 16 (43.2%) 14 (37.8%) 2 (5.4%) 1 (2.7%) 14 (37.8%) 6 (16.2%) –
Total (n=58) – 30 (51.7%) 24 (41.4%) 4 (6.9%) – 28 (48.3%) 21 (36.2%) 2 (3.4%) 1 (1.7%) 25 (43.1%) 14 (24.1%) –
Entire study population (n=118) 6 (5.1%) 56 (47.4%) 46 (39%) 10 (8.5%) 1 (0.8%) 57 (48.3%) 42 (35.6%) 2 (1.7%) 2 (1.7%) 51 (43.2%) 28 (23.7%) –
a p<0.05, for comparison between generalized and focal groups.
b p<0.05, for comparison between generalized and focal evolving to bilateral seizure groups.
c p<0.05, for comparison between generalized and mixed groups.
d p<0.05, for comparison between focal and focal evolving to bilateral seizure groups.
A
.
 V
erro
tti
 et
 a
l.
 /
 Seizu
re
 2
2
 (2
0
1
3
)
 2
1
0
–
2
1
6
 
2
1
3
Table 3
Incidence of side effects during treatment period.
Adverse eventsa Group A (n = 59) Group B (n = 59) Total (n = 118)
n (%) n (%) n (%)
Dizziness 2 (3.4%) 6 (10.2%) 8 (6.8%)
Headache 3 (5.1%) 4 (6.8%) 7 (5.9%)
Somnolence 2 (3.4%) 3 (5.1%) 5 (4.3%)
Vomiting 3 (5.1%) 2 (3.4%) 5 (4.3%)
Dyspepsia 4 (6.8%) 1 (1.7%) 5 (4.3%)
Nausea 3 (5.1%) 1 (1.7%) 4 (3.4%)
Irritability 3 (5.1%) 1 (1.7%) 4 (3.4%)
Inappetence – 2 (3.4%) 2 (1.7%)
Diplopia – 2 (3.4%) 2 (1.7%)
Paresthesia 1 (1.7%) 1 (1.7%) 2 (1.7%)
Balance disorder 1 (1.7%) – 1 (0.8%)
Abdominal pain 1 (1.7%) – 1 (0.8%)
Fatigue 1 (1.7%) – 1 (0.8%)
Lightheadedness – 1 (1.7%) 1 (0.8%)
Status epilepticus – 1 (1.7%) 1 (0.8%)
a Patients could have more than one adverse event.
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withdrew from the study after the 3-month evaluation because of
adverse events.
Of 102 patients reaching the 6-month follow-up, only 1 (0.8%)
patient (0% group A; 1.7% group B; p = 1) continued to be seizure
free, 57 (48.3%) subjects (52.5% group A; 44.1% group B; p = 0.4612)
were 50% responders and 42 (35.6%) were non-responders (32.2%
group A; 39% group B; p = 0.5641). An increase in seizure frequency
was reported in 2 (1.7%) patients (0% group A; 3.4% group B;
p = 0.4757) that had to discontinue lacosamide therapy; other 15
patients discontinued treatment after the 6-month follow-up
because of lack of efﬁcacy (4 group A, 14 group B) or side effects (1
group B).
Out of 81 patients reaching the 12-month evaluation, 2 (1.7%)
subjects (0% group A; 3.4% group B; p = 0.4757) were seizure free,
51 (43.2%) continued to be 50% responders (47.4% group A; 39%
group B; p = 0.4573) and 28 (23.7%) did not respond to therapy
(30.5% group A; 16.9% group B; p = 0.1298).
3.2.2. Efﬁcacy by seizure type
Data analysis by seizure type showed different responses to
lacosamide treatment (Table 2).
The 50% responder rates at 3, 6 and 12-month evaluations were
25%, 6.3% and 25% in subjects with generalized seizures; 44.8%,
63.2% and 62.1% in the focal seizure group; 60%, 40% and 26.7% in
subjects with focal seizure evolving to bilateral convulsive
seizures; 51.7%, 48.3% and 43.1% in patients with mixed seizures.
More precisely, within the focal group, 3 of the 7 patients with
simple partial seizures and 14 of the 22 subjects with complex
partial seizures were 50% responders at 12 months. Interestingly,
comparing the 50% responder rates at 12 months between the
different seizure type groups, a signiﬁcant difference was found
only between focal and generalized seizure groups (p = 0.0291).
Of 16 patients with generalized epilepsy, seizure freedom was
achieved in 12.5%, 6.3% and 6.3% at 3, 6 and 12-month follow-up. Of
29 patients suffering from focal seizures, 13.8% was seizure free at 3
months but no patient was seizure free at 6 and 12 months. Among
15 subjects with focal seizures evolving to bilateral convulsive
seizures, no subject achieved 100% reduction in seizure frequency.
The non-responder rates at 3, 6 and 12-month follow-up were
31.2%, 25% and 12.5% in the generalized seizure group; 37.9%, 31%
and 17.2% in patients with focal seizures; 40%, 53.3% and 46.7% in
subjects with focal seizure evolving to bilateral convulsive
seizures; 41.4%, 36.2% and 24.1% in the mixed seizure group.
At 3 months an increase in seizure frequency was observed in
31.2%, 3.5%, 0% and 6.9% of patients with generalized, focal, focal
with secondary generalization and mixed seizures, respectively. At
6 months only 3.4% of patients with mixed seizures had an increase
in seizure frequency. At 12 months no increase in seizure
frequency occurred.
Discontinuation rates over the entire lacosamide treatment
period were 56.3% for generalized seizure group, 20.7% for focal
seizure group, 26.7% for focal evolving to bilateral convulsive
seizure group and 31% for mixed seizure group. Comparing the
discontinuation rates between the different seizure type groups, a
signiﬁcant difference (p = 0.0234) was found only between
generalized and focal groups.
3.3. Safety
Out of 118 treated patients, 35 (29.7%) experienced side effects
(30.5% group A; 28.8% group B; p = 1) during the treatment period
(Table 3). The most common adverse events were dizziness,
headache, somnolence, dyspepsia, vomiting, irritability, and
nausea. Other side effects included paresthesia, diplopia, inappe-
tence, balance disorder, fatigue, abdominal pain, lightheadedness.One patient experienced status epilepticus. Adverse events
generally had an onset during the titration period. Most of the
reported side effects were mild to moderate in intensity and
resolved by slowing the titration rate of lacosamide.
Seven subjects withdrew from the study prematurely during
the maintenance period because of side effects: 2 patients in the
group A and 5 in the group B. Side effects leading to discontinua-
tion were: vomiting (2 group A; 1 group B), vertigo (3 group A) and
status epilepticus (1 group B).
Overall results of clinical laboratory tests as well as periodic
physical examinations, neurological examinations, and assess-
ments of vital signs did not reveal any changes associated with
lacosamide treatment. Mean plasma concentrations of the
concomitant AEDs as well as body weight were not affected by
concomitant intake of lacosamide.
4. Discussion
This multicenter, prospective, open label treatment study
demonstrates that adjunctive therapy with oral lacosamide
similarly reduces seizure frequency in pediatric and adult patients
with uncontrolled generalized and focal epilepsy. This study
conﬁrms the clinical efﬁcacy of lacosamide in refractory epilepsy
and corroborates ﬁndings from previous studies.
The safety and efﬁcacy of add-on lacosamide in adults with
uncontrolled partial-onset seizures were evaluated in three
double-blind, placebo-controlled trials and two open-label stud-
ies.9,10,16,17 A favorable outcome of at least 50% seizure reduction
was reported in 33–41% of the patients treated with lacosamide
200–600 mg/day. The 50% responder rate in our group of adults
with refractory epilepsy (39%) was generally in accordance with
these results. In the present study, as well as in the previous clinical
trials,8–10,16,17 lacosamide was well tolerated in adults; adverse
events occurred at a low frequency and were related to the nervous
and gastrointestinal systems including dizziness, headache,
nausea, vomiting, diplopia and somnolence; side effects generally
had an onset during the titration period. The discontinuation rate
because of side effects ranged from 8.7% to 17% in the previous
studies and was similar to that observed in our study (8.5%).
Postmarketing experience with adjunctive lacosamide in adoles-
cent and adult patients with pharmacoresistant epilepsy yielded
similar results.18–21
Recent studies conducted in children and adolescents with
refractory epilepsy showed a favorable outcome.11–14 In the ﬁrst
study,11 18 patients were enrolled and they completed a mean of 8
months lacosamide treatment, lacosamide was administered
A. Verrotti et al. / Seizure 22 (2013) 210–216 215orally, in the form of syrup or tablets twice daily with a ﬁnal dose
ranged between 1.7 and 10 mg/kg (mean = 6.3). At the ﬁrst
assessment, 36% of patients experienced a reduction of more than
50% seizure frequency, and two children achieved seizure freedom.
Another two studies12,13 retrospectively reviewed charts for
lacosamide use and seizure frequency outcome in children with
focal epilepsy; they respectively identiﬁed 16 and 17 patients. In
the ﬁrst study12 the mean age was 14.9 years and the median
maintenance dose of lacosamide was 275 mg/day, while, in the
second,13 children aged 1.5–16 years were treated at doses up to
20 mg/kg/day. Similarly to previous reports in adults, these
retrospective studies revealed a favorable outcome in pediatric
patients, in particular the ﬁrst study12 reported a 39.6% seizure
reduction rate. The last study was performed in 2012: Rastogi and
Ng14 reviewed 21 pediatric patients aged up to 17 years who were
treated with oral lacosamide as part of a prospective add-on study
as adjunctive therapy for refractory epilepsy. Maintenance dosages
of lacosamide ranged from 2.4 to 19.4 mg/kg/day. Fifty percent of
patients had greater than 50% reduction in seizure frequency and,
on the other hand, 50% of patients had generalized epilepsy; at
study end, lacosamide was shown to be an effective therapy,
particularly for partial-onset seizures. The 50% responder rate
reported in those studies, ranging from 35% to 50%, was in
accordance to that observed in our group of pediatric patients
(47.4%). Adverse events occurred in 37.5–59% of subjects and
included mostly somnolence, dizziness, nausea and irritability11–
14; treatment was discontinued in 0–25% of patients because of
side effects.11–14 In the present study the incidence of adverse
events in pediatric population was 29.7% and discontinuation rate
due to side effects was 3.4%.
The efﬁcacy and safety of lacosamide in pediatric and adult
patients were compared in the present study. During the whole
treatment period with lacosamide, the 50% responder rates in
group A were comparable to those reported in group B. No
signiﬁcant difference in the incidence of side effects between
group A and group B was found. The most common side effect
reported in group A was dyspepsia in contrast with dizziness
observed in group B. Discontinuation rate appeared signiﬁcantly
higher in group B than in group A since most of non-responders in
group B compared to those in group A discontinued treatment
prematurely due to lack of efﬁcacy.
Based on seizure type, marked differences in efﬁcacy outcomes
were observed. Patients suffering from generalized seizures
showed a poor response to lacosamide therapy in both groups A
and B; on the other hand, the best response to lacosamide
treatment was observed in patients suffering from focal seizures,
as recently observed by Rastogi and Ng.14 These subjects showed
the lowest discontinuation rate and the highest 50% responder rate
in both groups A and B.
As recently suggested, the different response to treatment with
lacosamide in patients taking 1–4 background AEDs could be
linked to its mechanism of action. Stephen et al. demonstrated
that the pharmacological effect of lacosamide differs importantly
from sodium channel blocking AEDs.22 In the post hoc exploratory
analysis of pooled phase II/III lacosamide clinical trial data,
patients taking only AEDs that act on non-sodium channel targets
experienced excellent seizure control with the addition of LCM
compared with placebo; LCM was well tolerated and had a lower
rate of discontinuation for adverse events (8.6%) compared with
the pooled phase II/III population (17.5%).23 In our experience, of
37 patients discontinuing treatment, 14 were taking sodium
valproate in addition to lacosamide and most of them discon-
tinued because of aggravated seizures. Since many patients in this
study simultaneously received various AEDs, it is difﬁcult to
determine whether there is any speciﬁc drug synergy with
lacosamide.In conclusion, results from this prospective open label study
demonstrate that lacosamide has a similar efﬁcacy and safety
proﬁle in children compared with adults. Therefore, our experience
suggests that lacosamide could be a very good choice for pediatric
patients with uncontrolled seizures. However, the short-term
follow-up, as well as the nature of this study and the lack of
randomization, does not allow us to make ﬁrm conclusions. Large,
randomized controlled studies are needed to validate our ﬁndings.
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